SEARCH:   Advanced

Blood, 1 September 2008, Vol. 112, No. 5, pp. 1993-2003. Prepublished online as a Blood First Edition Paper on April 24, 2008; DOI 10.1182/blood-2007-07-099432. This Article Full Text Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2007-07-099432v1 112/5/1993    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kujawski, L. Articles by Malek, S. N. Search for Related Content PubMed PubMed Citation Articles by Kujawski, L. Articles by Malek, S. N. Related Collections Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia Lisa Kujawski1,*, Peter Ouillette1,*, Harry Erba1, Chris Saddler1, Andrzej Jakubowiak1, Mark Kaminski1, Kerby Shedden2, and Sami N. Malek1 1 Department of Internal Medicine, Division of Hematology and Oncology, and 2 Department of Statistics, University of Michigan, Ann Arbor Chronic lymphocytic leukemia (CLL) has a variable clinical course. Presence of specific genomic aberrations has been shown to impact survival outcomes and can help categorize CLL into clinically distinct subtypes. We studied 178 CLL patients enrolled in a prospective study at the University of Michigan, of whom 139 and 39 were previously untreated and previously treated, respectively. We obtained unbiased, high-density, genome-wide measurements of subchromosomal copy number changes in highly purified DNA from sorted CD19+ cells and buccal cells using the Affymetrix 50kXbaI SNP array platform (Santa Clara, CA). Genomic complexity scores were derived and correlated with the surrogate clinical end points time to first therapy (TTFT) and time to subsequent therapy (TTST): measures of disease aggressiveness and/or therapy efficaciousness. In univariate analysis, progressively increasing complexity scores in previously untreated CLL patients identified patients with short TTFT at high significance levels. Similarly, TTST was significantly shorter in pretreated patients with high as opposed to low genomic complexity. In multivariate analysis, genomic complexity emerged as an independent risk factor for short TTFT and TTST. Finally, algorithmic subchromosomal complexity determination was developed, facilitating automation and future routine clinical application of CLL whole-genome analysis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Genomic complexity in chronic lymphocytic leukemia Thomas J. Kipps Blood 2008 112: 1550. [Full Text] [PDF] This article has been cited by other articles: T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020